JDRF Criticizes Medtronic/UHC For Reducing Patient Choice

JDRF has issued a press release criticizing UnitedHealthcare’s decision to extend Medtronic’s exclusive status for supplying insulin pumps to its covered lives. Recall, Medtronic first signed the deal with UHC in May 2016, which applied to patients 18 years of age and older. However, with FDA’s approval of the 670G pump in patients down to 7 years of age, UHC has extended the agreement to this population. Patients on existing pump therapy or patch pumps (e.g. Insulet Omnipod) are not impacted. Below, FENIX provides thoughts on UHC’s decision, the potential impact to Tandem’s pump business, and the potential irony of JDRF’s criticism.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.